{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:44:24Z","timestamp":1785793464759,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijgc.2026.104761","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:13:56Z","timestamp":1778861636000},"page":"104761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral cyclophosphamide combined with bevacizumab in recurrent heavily pre-treated ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6651-3781","authenticated-orcid":false,"given":"Mostafa F.","family":"Eyada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-9123","authenticated-orcid":false,"given":"Shrina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1446-9574","authenticated-orcid":false,"given":"Jeffrey A.","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-9441","authenticated-orcid":false,"given":"Roni Nitecki","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-4151","authenticated-orcid":false,"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole D.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela T.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-0795","authenticated-orcid":false,"given":"Travis T.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2026.104761_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104761_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104761_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.23.01771","article-title":"Treatment approaches for platinum-resistant ovarian cancer","volume":"42","author":"St Laurent","year":"2024","journal-title":"J Clin Oncol."},{"issue":"14","key":"10.1016\/j.ijgc.2026.104761_bib4","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104761_bib5","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.ijgc.2026.104761_bib6","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/S0002-9378(94)70338-8","article-title":"Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial","volume":"170","author":"Seewaldt","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104761_bib7","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104761_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","article-title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","volume":"26","author":"Van Gorp","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10538","key":"10.1016\/j.ijgc.2026.104761_bib9","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"issue":"suppl 17","key":"10.1016\/j.ijgc.2026.104761_bib10","article-title":"Rosella: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72)","volume":"43","author":"Olawaiye","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104761_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104761_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104761_bib13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3802\/jgo.2013.24.3.258","article-title":"The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer","volume":"24","author":"Barber","year":"2013","journal-title":"J Gynecol Oncol"},{"issue":"1-2","key":"10.1016\/j.ijgc.2026.104761_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000320602","article-title":"Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer","volume":"79","author":"S\u00e1nchez-Mu\u00f1oz","year":"2010","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104761_bib15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12094-008-0254-7","article-title":"Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer","volume":"10","author":"Jurado","year":"2008","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104761_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104761_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.ijgc.2026.104761_bib18","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ijgc.2026.104761_bib19","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104761_bib20","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1535-7163.MCT-09-0583","article-title":"Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models","volume":"8","author":"Daenen","year":"2009","journal-title":"Mol Cancer Ther"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:47:52Z","timestamp":1785790072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26002926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1048891X26002926"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104761","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral cyclophosphamide combined with bevacizumab in recurrent heavily pre-treated ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104761"}}